Full name
This study is an observational, multi-centre prospective cohort study. The study will be conducted in adult participants with a confirmed primary diagnosis of either Severe eosinophilic asthma (SEA) with comorbid nasal polyposis (NP) or Chronic rhinosinusitis with nasal polyposis (CRSwNP) with comorbid asthma in a real-world setting.
NCT Number
GSK Identifier:218616
Geography
Non-US
Locations
Austria, France, Germany, Greece, Italy, Spain, United Kingdom
Primary Endpoints
Mean Change from Baseline in Sino-Nasal Outcome Test-22 (SNOT-22) at 12 months
External Link
https://www.gsk-studyregister.com/218616
Order
0
Disease
Version
Phase
Phase N/A
QR code description
Scan QR Code to view the Study Summary on the GSK Study Register site
Status
Active, not recruiting